Market Place
Sourcing Support
All News #Library
Biotech
Qilu Inks $120M, AI-Enabled Cardiometabolic Pact With Insilico
27 Jan 2026 //
FIERCE BIOTECH
Arbutus Regains China Rights to Potential Hep B Cure from Qilu
25 Jun 2025 //
FIERCE BIOTECH
Arbutus Reacquires Greater China Rights to Imdusiran
25 Jun 2025 //
GLOBENEWSWIRE
Minghui Pharma Partners with Qilu to develop B7-H3 ADC in China
09 May 2025 //
PR NEWSWIRE
Qilu Pharma Unveils Results for QLS32015 Bispecific Antibody
25 Dec 2024 //
PR NEWSWIRE
Qilu`s 3 Cancer Immunotherapy Studies At ASCO 2024
06 Jun 2024 //
PR NEWSWIRE
Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab
06 Dec 2023 //
PR NEWSWIRE
Phase I Results for Qilu Pharmaceutical`s Iparomlimab (QL1604) Now Published
06 Nov 2023 //
PR NEWSWIRE
Qilu Pharmaceutical announces latest results from its clinical study on QL1706
25 Oct 2023 //
PR NEWSWIRE
Qilu Pharma to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023
19 Oct 2023 //
PR NEWSWIRE
Results of PhI Study of Qilu Pharma`s PD-1/CTLA-4 Iparomlimab/Tuvonralimab
11 May 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.